Okyo Pharma Ltd. (OKYO)
Market Closed
15 Jun, 20:00
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN $
1. 52
0
0%
$
58.32M Market Cap
- P/E Ratio
- Div Yield
79,760 Volume
0 Eps
$ 1.52
Previous Close Investors:
Want to track OKYO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
OKYO Pharma dry eye disease trial to get underway in the third quarter
OKYO Pharma Ltd (NASDAQ:OKYO) plans to begin a phase II clinical trial for OK-101, targeting neuropathic corneal pain (NCP), in the third quarter. In earlier studies, OK-101 showed significant pain relief for dry eye disease patients and reduced NCP in animal models.
Proactiveinvestors | 1 year ago
OKYO Pharma shares encouraging dry eye data
OKYO Pharma Ltd (NASDAQ:OKYO) has shared encouraging results from a phase II trial of its treatment candidate for dry eye disease. The study involved 240 patients and showed that 68% of them had improved by meeting both key measures: reduced conjunctival staining and ocular pain.
Proactiveinvestors | 1 year ago
